Revolution Medicine Pancreatic Cancer Access Strain
Decision brief
Answer first · skim in under a minute
Revolution Medicines' daraxonrasib has shown a dramatic overall survival benefit in pancreatic cancer, but patient demand is overwhelming the expanded access program. For pharma strategists, the supply-demand imbalance signals potential launch revenue upside and commercial execution risk.
Revolution medicine pancreatic cancer headlines center on daraxonrasib’s Phase 3 survival gain and a new expanded-access path. Strong efficacy news can outrun investigational supply. Here is what SEC, FDA, and ClinicalTrials.gov establish for access and BD planning.
Contents10 sections
Key Takeaways
- April 13, 2026 Form 8-K: RASolute 302 showed median OS 13.2 vs 6.7 months (HR 0.40; p<0.0001) for daraxonrasib versus chemotherapy in previously treated metastatic PDAC.
- May 1, 2026 FDA announcement: safe-to-proceed letter for an expanded access protocol after an April 28 request signed April 30.
- NCT07573215 lists the EAP as available for eligible previously treated metastatic pancreatic adenocarcinoma patients unable to join trials.
- First-line Phase 3 NCT07491445 remains recruiting (~900 planned), so commercial-scale demand is still ahead of approval.
What did RASolute 302 show?
Revolution Medicines’ 8-K states daraxonrasib taken orally once daily demonstrated statistically significant and clinically meaningful improvements in PFS and OS versus standard intravenous cytotoxic chemotherapy in previously treated metastatic PDAC. In the overall intent-to-treat population, median OS was 13.2 months versus 6.7 months (HR 0.40; p < 0.0001).
The company described the drug as generally well tolerated with a manageable safety profile and no new safety signals at that interim analysis, which it treated as final for PFS and OS endpoints. It intends to submit data to global regulators, including an FDA NDA under a Commissioner’s National Priority Voucher pathway referenced in the filing.
Why is Revolution medicine pancreatic cancer demand stressing access channels?
Metastatic PDAC has high unmet need. When a randomized Phase 3 signal nearly doubles median OS versus chemotherapy in a disclosed ITT analysis, clinician and patient inquiries surge before commercial manufacturing is online.
Expanded access is designed for patients with no satisfactory alternatives who cannot enter trials. That channel is finite: eligibility screens, site activation, and investigational product allotments constrain throughput even when FDA has cleared a protocol to proceed.
What did FDA authorize on expanded access?
FDA’s May 1, 2026 press announcement says the agency issued a safe-to-proceed letter so Revolution Medicines can initiate an EAP for previously treated metastatic PDAC. The request arrived April 28 and was signed April 30. FDA notes prior Breakthrough Therapy and Orphan Drug designations and references the company’s April 13 NDA/CNPV intent.
ClinicalTrials.gov records NCT07573215 as an available expanded access program sponsored by Revolution Medicines, describing oral once-daily daraxonrasib (RMC-6236) supplied free during treatment under the program.
What else is running in the clinic?
NCT07491445 is a global randomized Phase 3 first-line metastatic pancreatic adenocarcinoma study comparing daraxonrasib monotherapy, daraxonrasib plus gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone, with estimated enrollment around 900. Primary completion estimates extend into 2028 on the registry page.
Portfolio strategy teams should not equate second-line Phase 3 success with first-line readiness; separate endpoints, combinations, and manufacturing scale still gate those indications.
BD and medical-affairs implications
- Model EAP versus trial versus future commercial funnels separately.
- Watch manufacturing scale-up disclosures in subsequent 8-K/10-Q exhibits.
- Track CNPV and NDA timing without assuming approval dates.
- Benchmark competitor RAS programs on mutation coverage—company materials describe daraxonrasib as a RAS(ON) multi-selective inhibitor, not a single-mutation anecdote.
What remains unproven
This article does not claim FDA approval, a verified waitlist length, or a quantified EAP denial rate. Prior draft language that “nearly doubled OS” without citing 13.2 vs 6.7 months is replaced by the 8-K figures. Claims that data were only presented in June 2026 conflict with the April 13, 2026 SEC disclosure date used here.
Related NovaPharma coverage
- BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
- Breast Cancer Statistics Worldwide: What the Data Shows
- Eli Lilly gene therapy cholesterol deals
Frequently Asked Questions
What did Revolution Medicines report for daraxonrasib in RASolute 302?
In an April 13, 2026 Form 8-K, Revolution Medicines reported that oral daraxonrasib improved median overall survival to 13.2 months versus 6.7 months for chemotherapy in previously treated metastatic PDAC (hazard ratio 0.40; p < 0.0001) in the intent-to-treat population.
What is the FDA expanded access status for daraxonrasib?
On May 1, 2026, FDA announced it issued a safe-to-proceed letter allowing Revolution Medicines to initiate an expanded access treatment protocol for previously treated metastatic PDAC; ClinicalTrials.gov lists NCT07573215 as available.
Is daraxonrasib FDA-approved for pancreatic cancer?
No. Company disclosures describe NDA planning, including intent to use a Commissioner’s National Priority Voucher pathway, while the product remains investigational with EAP and ongoing Phase 3 programs such as NCT07491445 in the first-line setting.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for daraxonrasib.
Unlock full calendar →Revolution Medicines pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
